Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. W. Majeed is active.

Publication


Featured researches published by A. W. Majeed.


British Journal of Surgery | 2004

Randomized clinical trial of laparoscopic versus open fundoplication for gastro-oesophageal reflux disease.

Roger Ackroyd; D. I. Watson; A. W. Majeed; G. Troy; P. J. Treacy; C. J. Stoddard

The aim of this study was to compare laparoscopic and open Nissen fundoplication for gastro‐oesophageal reflux disease in a randomized clinical trial.


Liver International | 2003

The molecular physiology of liver regeneration following partial hepatectomy.

David Mangnall; Nigel C. Bird; A. W. Majeed

Abstract: The ability of the liver to regenerate after resection has been known for many years. Two reports from Germany in the late 1800s probably mark the introduction of the phenomenon into the scientific literature, but in the early 1900s the first reviews of this subject had appeared in the English literature. Predating these early scientific reports the legends from the Greek mythology described the fate of Prometheus. As punishment for defying Zeus and revealing the secret of fire to man, Prometheus was chained to a rock and each day had part of his liver ripped out by an eagle which, returning the following day, repeated the torture because his liver regenerated itself overnight. Although the speed of regeneration in the Greek legend is somewhat greater than that observed either clinically or in the laboratory, the myth does serve to emphasise the remarkable ability of the liver to repeatedly regenerate following repeated resections. This review aims to summarise the more recent literature concerning the early molecular events accompanying liver regeneration and to integrate this with the existing knowledge of this subject.


Cancer Research | 2013

The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications

G. Van den Eynden; A. W. Majeed; Martin Illemann; P. Vermeulen; Nigel C. Bird; Gunilla Høyer-Hansen; Rikke Løvendahl Eefsen; Andrew R. Reynolds; Pnina Brodt

The liver is host to many metastatic cancers, particularly colorectal cancer, for which the last 2 decades have seen major advances in diagnosis and treatment. The liver is a vital organ, and the extent of its involvement with metastatic disease is a major determinant of survival. Metastatic cells arriving in the liver via the bloodstream encounter the microenvironment of the hepatic sinusoid. The interactions of the tumor cells with hepatic sinusoidal and extrasinusoidal cells (endothelial, Kupffer, stellate, and inflammatory cells) determine their fate. The sinusoidal cells can have a dual role, sometimes fatal to the tumor cells but also facilitatory to their survival and growth. Adhesion molecules participate in these interactions and may affect their outcome. Bone marrow-derived cells and chemokines also play a part in the early battle for survival of the metastases. Once the tumor cells have arrested and survived the initial onslaught, tumors can grow within the liver in 3 distinct patterns, reflecting differing host responses, mechanisms of vascularization, and proteolytic activity. This review aims to present current knowledge of the interactions between the host liver cells and the invading metastases that has implications for the clinical course of the disease and the response to treatment.


Molecular Cancer Research | 2006

MMP-9 Is Differentially Expressed in Primary Human Colorectal Adenocarcinomas and Their Metastases

Martin Illemann; Nigel C. Bird; A. W. Majeed; Maxwell Sehested; Ole Didrik Laerum; Leif R. Lund; Keld Danø; Boye Schnack Nielsen

Matrix metalloproteinase-9 (MMP-9) is up-regulated in macrophages in various human cancer types. In human colon cancer, MMP-9 is expressed in a macrophage subpopulation located at the tumor edge, indicating a specific induction of MMP-9 in macrophages in direct association with cancer invasion. To test whether MMP-9 is also induced in tumor edge macrophages in metastases from colorectal adenocarcinomas, we have compared the expression pattern of MMP-9 in primary colorectal adenocarcinomas (n = 15) with that in liver metastases (n = 15) and local lymph node metastases (n = 7) from the same patients by in situ hybridization and immunohistochemistry. In all the colorectal adenocarcinomas, the expression of MMP-9 mRNA and immunoreactivity in macrophages was located at the invasive front. In contrast, only 3 of the 15 liver metastases had MMP-9 mRNA and immunoreactivity at the periphery, and this expression was confined to small foci of macrophages located either among lymphocytes or in a dense desmoplastic stroma. Expression of MMP-9 mRNA and immunoreactivity was in all liver metastases seen in macrophages located in the lumen of malignant glandular structures and in central necrotic tissue. In all the 7 lymph node metastases, MMP-9 mRNA and immunoreactivity was seen in macrophages located in the stromal tissue surrounding the metastases. We conclude that MMP-9 is not up-regulated in tumor edge macrophages in liver metastases like in their primary tumor and local lymph node metastases, suggesting that disseminating colorectal cancer cells can adopt alternative proteolytic mechanisms for invasion depending on the local microenvironment. (Mol Cancer Res 2006;4(5):293–302)


International Journal of Cancer | 2009

Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases

Martin Illemann; Nigel C. Bird; A. W. Majeed; Ole Didrik Laerum; Leif R. Lund; Keld Danø; Boye Schnack Nielsen

Metastatic growth and invasion by colon cancer cells in the liver requires the ability of the cancer cells to interact with the new tissue environment. Plasmin(ogen) is activated on cell surfaces by urokinase‐type PA (uPA), and is regulated by uPAR and plasminogen activator inhibitor‐1 (PAI‐1). To compare the expression patterns of uPA, uPAR and PAI‐1 in colon cancer with that in their liver metastases, we analysed matched samples from 14 patients. In all 14 primary colon cancers, we found upregulation of uPAR, uPA mRNA and PAI‐1 in primarily stromal cells at the invasive front. In 5 of the 14 liver metastases, we found intense expression of uPAR, uPA‐mRNA and PAI‐1 in primarily stromal cells at the metastases periphery, and in an expression pattern similar to that found in the primary tumours. In the remaining 9 liver metastases, uPAR and uPA‐mRNA were only seen associated with the presence of necrosis within the liver metastases. In addition, PAI‐1‐immunoreactivity was in all liver metastases seen in hepatocytes at the metastases periphery. Interestingly, the former 5 liver metastases positive for uPAR, uPA mRNA and PAI‐1 at the metastasis periphery all had a predominantly desmoplastic reaction, whereas 8 of the remaining 9 showed direct contact between the cancer cells and the liver parenchyma. We conclude that there are 2 distinct patterns of expression of uPAR, uPA and PAI‐1 in colon cancer liver metastases and that these correlate closely with 2 morphological growth patterns. These findings may have implication for the treatment of patients with metastatic disease.


The American Journal of Gastroenterology | 2005

Prediction of Malignant Potential in Reflux Disease: Are Cytokine Polymorphisms Important?

Martin Gough; Roger Ackroyd; A. W. Majeed; Nigel C. Bird

OBJECTIVES:Esophageal reflux is common in the Western world and can lead to a number of diseases, such as esophagitis, Barretts esophagus, and adenocarcinoma. Barretts predisposes to adenocarcinoma and endoscopic surveillance may lead to earlier detection of adenocarcinoma. However, clinical methods only identify one patient in 15 with Barretts esophagus. The aim of this study was to find factors that may help identify patients with Barretts earlier.METHODS:Blood samples and detailed histories were taken from 456 patients with gastroesophageal reflux who were recruited into three study groups: esophagitis, Barretts esophagus without dysplasia, and Barretts with dysplasia or adenocarcinoma. PCR was used to determine the frequency of five functional cytokine polymorphisms: interleukin-1 receptor antagonist position +2018 (IL-1 Ra +2018), interleukin-1 β position −511 (IL-1 β −511), tumor necrosis factor-α position −238 (TNF-α −238), interleukin-10 position +1082 (IL-10 +1082), and interleukin-4 receptor position −1902 (IL-4R −1902).RESULTS:IL-1 Ra +2018 genotype 2/2 was associated with Barretts more commonly than esophagitis (OR-3.7, p = 0.0345). The IL-10 +1082 genotype 2/2 was more strongly associated with Barretts and adenocarcinoma than esophagitis (OR-1.76, p = 0.056 and OR 1.96, p = 0.025, respectively). There were no differences for the IL-1 β −511, IL-4R −1902, and TNF-α −238 polymorphisms.CONCLUSIONS:Cytokine polymorphisms are more commonly found in patients with Barretts or adenocarcinoma than those with esophagitis. Together with demographic data, this may help identify those patients with Barretts who would benefit from surveillance.


Hepatology Research | 2010

Role of Kupffer cells in the outgrowth of colorectal cancer liver metastases

Konstantinos A. Paschos; A. W. Majeed; Nigel C. Bird

Colorectal cancer is one of the commonest malignancies in the “developed” world. The liver constitutes the main host organ for its distant metastases which, when present, augur a bad prognosis for the disease. Kupffer cells (KCs) are macrophages that constantly reside within the liver and form an effective first line defence against multiple harmful agents which reach the hepatic sinusoids via the portal circulation. KCs remove chemical compounds and dead or damaged cells, eliminate bacteria and protect against invading tumour cells. They may play a crucial tumouricidal role, exerting cytotoxic and cytostatic functions through the release of multiple cytokines and chemokines. Subsequently, colorectal metastasising cells are destroyed either by KC‐performed phagocytosis or via the stimulation of other immune cells which migrate into the sinusoids and act accordingly. On the contrary, KC products, including cytokines, growth factors and matrix‐degrading enzymes may promote liver metastasis, supporting tumour cell extravasation, motility and invasion. Current research aims to exploit the antineoplastic properties of KCs in new therapeutic approaches of colorectal cancer liver metastasis. Numerous agents, such as the granulocyte macrophage‐colony stimulating factor, interferon gamma, muramyl peptide analogues and various antibody based treatments, have been tested in experimental models with promising results. Future trials may investigate their use in everyday clinical practice and compare their therapeutic value with current treatment of the disease.


World Journal of Gastroenterology | 2014

Natural history of hepatic metastases from colorectal cancer - pathobiological pathways with clinical significance

Konstantinos A. Paschos; A. W. Majeed; Nigel C. Bird

Colorectal cancer hepatic metastases represent the final stage of a multi-step biological process. This process starts with a series of mutations in colonic epithelial cells, continues with their detachment from the large intestine, dissemination through the blood and/or lymphatic circulation, attachment to the hepatic sinusoids and interactions with the sinusoidal cells, such as sinusoidal endothelial cells, Kupffer cells, stellate cells and pit cells. The metastatic sequence terminates with colorectal cancer cell invasion, adaptation and colonisation of the hepatic parenchyma. All these events, termed the colorectal cancer invasion-metastasis cascade, include multiple molecular pathways, intercellular interactions and expression of a plethora of chemokines and growth factors, and adhesion molecules, such as the selectins, the integrins or the cadherins, as well as enzymes including matrix metalloproteinases. This review aims to present recent advances that provide insights into these cell-biological events and emphasizes those that may be amenable to therapeutic targeting.


Comparative Hepatology | 2004

Early increases in plasminogen activator activity following partial hepatectomy in humans

David Mangnall; Kirsty Smith; Nigel C. Bird; A. W. Majeed

BackgroundIncreases in urokinase-like plasminogen activator (uPA) activity are reported to be amongst the earliest events occurring in remnant liver following partial hepatectomy in rats, and have been proposed as a key component of the regenerative response. Remodelling of the extracellular matrix, conversion of single chain hepatocyte growth factor to the active two-chain form and a possible activation of a mitogenic signalling pathway have all been ascribed to the increased uPA activity. The present study aimed to determine whether similar early increases in uPA activity could be detected in the remnant liver following resection of metastatic tumours in surgical patients.ResultsEighteen patients undergoing partial hepatectomy for the removal of hepatic metastases secondary to primary colonic tumours were studied. Increased plasminogen activator activity was found in the final liver samples for the group of patients in whom the resection size was at least 50%. For smaller resections, the increased activity was not observed. The increased activity did not correlate with the age of the patient or with the time between the start of resection and the end of the operation. There was, however, a negative correlation between plasminogen activator activity and the time for which blood supply to the liver was clamped.ConclusionsOur findings are in accordance with those from experimental animal models and show, for the first time, that rapid increases in plasminogen activator activity can occur following similarly large liver resection in humans. Thus, increases in plasminogen activator activity are an early event in the remnant liver following major liver resection in man. Our observations provide support for the contention that increases in plasminogen activators play a key role in the initiation of hepatic regeneration in man.


British Journal of Cancer | 2017

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

Pieter-Jan van Dam; Eric P. van der Stok; Laure-Anne Teuwen; Gert Van den Eynden; Martin Illemann; Sophia Frentzas; A. W. Majeed; Rikke L. Eefsen; Robert R.J. Coebergh van den Braak; Anthoula Lazaris; Maria Celia Fernandez; Boris Galjart; Ole Didrik Laerum; Roni F. Rayes; Dirk J. Grünhagen; Michelle Van de paer; Yves Sucaet; Hardeep Singh Mudhar; Michael Schvimer; Hanna Nyström; Mark Kockx; Nigel C. Bird; Fernando Vidal-Vanaclocha; Peter Metrakos; Eve Simoneau; Cornelis Verhoef; Luc Dirix; Steven Van Laere; Zu-Hua Gao; Pnina Brodt

Background:Liver metastases present with distinct histopathological growth patterns (HGPs), including the desmoplastic, pushing and replacement HGPs and two rarer HGPs. The HGPs are defined owing to the distinct interface between the cancer cells and the adjacent normal liver parenchyma that is present in each pattern and can be scored from standard haematoxylin-and-eosin-stained (H&E) tissue sections. The current study provides consensus guidelines for scoring these HGPs.Methods:Guidelines for defining the HGPs were established by a large international team. To assess the validity of these guidelines, 12 independent observers scored a set of 159 liver metastases and interobserver variability was measured. In an independent cohort of 374 patients with colorectal liver metastases (CRCLM), the impact of HGPs on overall survival after hepatectomy was determined.Results:Good-to-excellent correlations (intraclass correlation coefficient >0.5) with the gold standard were obtained for the assessment of the replacement HGP and desmoplastic HGP. Overall survival was significantly superior in the desmoplastic HGP subgroup compared with the replacement or pushing HGP subgroup (P=0.006).Conclusions:The current guidelines allow for reproducible determination of liver metastasis HGPs. As HGPs impact overall survival after surgery for CRCLM, they may serve as a novel biomarker for individualised therapies.

Collaboration


Dive into the A. W. Majeed's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. G. Johnson

Royal Hallamshire Hospital

View shared research outputs
Top Co-Authors

Avatar

A. Smythe

Royal Hallamshire Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A G Johnson

University of Sheffield

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roger Ackroyd

Royal Hallamshire Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge